Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

New Tool Uses NF-κB Activity to Classify HPV+ Head and Neck Cancer

Oncotarget

May 26, 2022
Researchers developed a new tool aimed at better classifying HPV+ HNSCC patients with good or poor prognosis in an effort to personalize treatment and improve patient outcomes. continue reading »

Oncotarget | NF-κB Over-Activation Portends Improved Outcomes in HPV+ HNSCC

News

May 25, 2022
PRESS RELEASE: On March 24, 2022, Oncotarget published a new research paper, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” continue reading »

Oncotarget: Anti-Cancer Drug Profiling With CancerOmicsNet

News

May 19, 2022
PRESS RELEASE: A new research paper was published in Volume 13 of Oncotarget, entitled, “CancerOmicsNet: a multi-omics network-based approach to anti-cancer drug profiling.” continue reading »

Trending With Impact: Dual Requirement in Stem Cell Leukemia/Lymphoma

Oncotarget

May 12, 2022
For the first time, researchers revealed the protein interactome, phospho-proteome and total proteome for the oncogenic fusion protein BCR-FGFR1. continue reading »

Gene Variants Investigated in Polish Bladder and Kidney Cancer

Oncotarget

April 27, 2022
Two gene variants were studied in large-scale cohorts for their potential roles in bladder and kidney cancer among Polish patients. continue reading »